Capital Analysts LLC’s DexCom DXCM Stock Holding History

Capital Analysts LLC’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5K	Hold	68	–	–	﹤0.01%	1386
2026 Q1	$4K	Hold	68	–	–	﹤0.01%	1383
2025 Q4	$5K	Hold	68	–	–	﹤0.01%	1336
2025 Q3	$5K	Hold	68	–	–	﹤0.01%	1296
2025 Q2	$6K	Hold	68	–	–	﹤0.01%	1215
2025 Q1	$5K	Hold	68	–	–	﹤0.01%	1221
2024 Q4	$5K	Hold	68	–	–	﹤0.01%	1150
2024 Q3	$5K	Hold	68	–	–	﹤0.01%	1115
2024 Q2	$8K	Hold	68	–	–	﹤0.01%	983
2024 Q1	$9K	Hold	68	–	–	﹤0.01%	929
2023 Q4	$8K	Hold	68	–	–	﹤0.01%	918
2023 Q3	$6K	Hold	68	–	–	﹤0.01%	948
2023 Q2	$9K	Sell	68 -64	-48%	-$7.74K	﹤0.01%	830
2023 Q1	$15K	Hold	132	–	–	﹤0.01%	765
2022 Q4	$15K	Buy	132 +43	+48%	+$4.72K	﹤0.01%	805
2022 Q3	$7K	Sell	89 -603	-87%	-$51.1K	﹤0.01%	848
2022 Q2	$52K	Hold	692	–	–	﹤0.01%	545
2022 Q1	$89K	Sell	692 -124	-15%	-$13.6K	0.01%	454
2021 Q4	$110K	Hold	816	–	–	0.01%	428
2021 Q3	$112K	Hold	816	–	–	0.01%	430
2021 Q2	$87K	Hold	816	–	–	0.01%	472
2021 Q1	$73K	Buy	+816	New	+$76.6K	0.01%	524

Other funds holding DXCM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital Analysts LLC's DXCM Position: Q2 2026 in Review

Capital Analysts LLC held its DexCom (DXCM) position steady in Q2 2026 at 68 shares worth $5K. The position accounts for ﹤0.01% of the portfolio, ranked #1386.

Capital Analysts LLC first reported a position in DXCM in Q1 2021 and has held it in 22 quarters since. The position peaked at $112K in Q3 2021. 968 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.

Capital Analysts LLC held 68 shares of DexCom worth $5K as of Q2 2026.
Capital Analysts LLC left its DexCom share count unchanged in Q2 2026.
DexCom made up ﹤0.01% of Capital Analysts LLC's portfolio in Q2 2026, its #1386 holding.
Capital Analysts LLC first reported a position in DexCom in Q1 2021 and has held it in 22 quarters since.
Capital Analysts LLC's DexCom position peaked at $112K in Q3 2021.
968 funds tracked by Wall St. Rank held DexCom as of Q2 2026.

Based on Capital Analysts LLC's 13F filing for Q2 2026, filed 5 Aug 2026.